Get Started

TOVX

AMEX Theriva Biologics, Inc.
Oct 30, 2026 · 9:32 PM ET EOD Market Closed

$0.1705 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.1705, $0.0171 below the day’s high of $0.1876

YTD change
-18.96%
vs 20-day SMA
-18.20%
vs 200-day SMA
-28.80%

Price ranges

Previous day
$0.1849 $0.1896
open $0.1866 close $0.1870
+$0.0004 (+0.21%)
Today
$0.1668 $0.1876
open $0.1870 now $0.1705
-$0.0165 (-8.82%)
Past week
$0.1838 $0.2000
from $0.1900 now $0.1705
-$0.0195 (-10.26%)
Past month
$0.1838 $0.2468
from $0.2250 now $0.1705
-$0.0545 (-24.22%)
This year
$0.1628 $0.4920
from $0.2104 now $0.1705
-$0.0399 (-18.96%)

Price & Performance

-0.19 (-52.45%) / 6M

$0.1530$0.2377$0.3224$0.4071Apr 30Jul 31Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 97.6% away from all-time highs of $7.1500
  • TOVX is down 19% since the beginning of the year
  • TOVX is down 47% over the past 12 months
  • TOVX is down 24% over the past 1 month
  • 4% of all TOVX investors are betting against TOVX
  • Number of investors short TOVX has gone up 5% versus last month

TOVX reads poor: price sits below both the 20- and 200-day averages, short interest is rising month over month, the 12-month move is -47.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.07
Earnings momentum -16.7% Quarterly EPS growth
Quarterly change -16.7%

Valuation

P/E ratio 0.26
Enterprise value $797.9K
Beta 1.23

Balance sheet & scale

IncomeN/A
Revenue$300.0K
Cash$11.3M
Debt$3.6K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeAMEX
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $7.8M

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $466.01 +1.15%
MRNA Moderna, Inc. $221.72 -0.47%
RVMD Revolution Medicines, Inc. $191.31 +0.55%
ROIV Roivant Sciences Ltd. $36.91 -1.63%
BNTX BioNTech SE Sponsored ADR $88.17 -1.08%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.